Shoulder mass - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Tissue biopsy of shoulder lesion.

₹666₹951

30% OFF

Shoulder Mass - Large Biopsy 3-6 cm

Why is it done?
- To obtain tissue samples from a shoulder mass measuring 3-6 cm in diameter for histopathological examination and diagnosis
- To differentiate between benign and malignant lesions of the shoulder region
- To determine the specific histological type and grade of soft tissue tumors or masses
- To identify infectious, inflammatory, or neoplastic processes affecting the shoulder
- When imaging studies (ultrasound, CT, or MRI) reveal an indeterminate shoulder mass requiring tissue confirmation
- To guide treatment decisions and staging in cases of suspected malignancy
- Typically performed when a palpable or radiographically detected mass persists longer than 4-6 weeks or shows concerning features
Normal Range
- Benign Findings (Normal/Expected): Lipoma, fibroma, hemangioma, ganglion cyst, or other clearly benign pathology with no cytologic atypia or mitotic activity
- Inflammatory/Infectious (Normal variants): Evidence of inflammation, infection, or granulation tissue consistent with benign processes
- Abnormal Findings (Positive): Malignant neoplasm with cellular atypia, increased mitotic figures, or features consistent with sarcoma, metastatic disease, or lymphoma
- Units of Measurement: Histopathological diagnosis (qualitative); tissue sections evaluated at 40x magnification under light microscopy; immunohistochemical markers as needed
- Interpretation Guide: Normal = benign histology with no malignant features; Abnormal = presence of malignancy, atypical cells, or concerning pathology requiring further intervention
Interpretation
- Benign Lesions: Includes lipomas, fibromas, hemangiomas, myositis ossificans, and other non-malignant soft tissue tumors; typically require no further intervention or only conservative management
- Soft Tissue Sarcomas: May indicate fibrosarcoma, leiomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma; requires staging studies and oncologic consultation
- Infectious/Inflammatory: May indicate abscess, tuberculosis, fungal infection, or inflammatory pseudotumor; appropriate antimicrobial or anti-inflammatory therapy indicated
- Metastatic Disease: May reveal carcinoma or melanoma metastases; indicates need for primary tumor identification and staging
- Lymphoproliferative Disorders: May indicate lymphoma or leukemic infiltration; flow cytometry and specialized immunophenotyping often recommended
- Factors Affecting Interpretation: Specimen adequacy, contamination, location of biopsy within mass (periphery vs. center), previous treatments, and associated radiographic findings
- Grading Systems: Tumors graded as low-grade, intermediate, or high-grade based on cellularity, necrosis, and mitotic activity; higher grades correlate with poorer prognosis
Associated Organs
- Primary Structures: Soft tissues of the shoulder including skin, subcutaneous fat, muscle, tendon, fascia, and nerve/vascular structures
- Organ Systems Involved: Integumentary system, musculoskeletal system, lymphatic system, and potentially systemic malignancies
- Common Associated Diagnoses: Lipoma, fibrosarcoma, synovial sarcoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, melanoma metastases, ganglion cyst, hemangioma, and shoulder joint infections
- Potential Complications from Abnormal Results: Malignant tumors may lead to local invasion, lymph node involvement, distant metastases, functional impairment, neurovascular compromise, and systemic complications requiring aggressive treatment
- Risk Factors for Malignancy: Rapid growth, size >5 cm, deep anatomic location, pain, neurologic symptoms, and prior radiation therapy
Follow-up Tests
- If Benign Diagnosis: Clinical follow-up with serial physical examination; repeat imaging only if symptomatic change occurs; no further testing typically required
- If Malignancy Confirmed: Staging CT chest/abdomen/pelvis, MRI for local extent assessment, PET-CT for metabolic activity and distant staging, bone scan if applicable
- Immunohistochemistry and Molecular Testing: Performed on initial biopsy specimen to identify specific tumor type, guide prognostication, and determine treatment eligibility (e.g., targetable mutations)
- Flow Cytometry: If lymphoma or leukemia suspected based on initial histology
- If Infection Identified: Culture and sensitivity testing, blood cultures, inflammatory markers (ESR, CRP), and appropriate antimicrobial therapy initiation
- Oncology Consultation: For any confirmed malignancy to determine need for surgery, chemotherapy, radiation, or targeted therapy
- Surgical Re-excision: May be needed if margin status is positive or for primary tumor treatment if biopsy performed via core needle technique
- Surveillance Imaging: Serial MRI every 3-6 months for first 2 years post-diagnosis if malignancy confirmed, then annually based on tumor grade and treatment response
Fasting Required?
- Fasting Required: No, fasting is not required for tissue biopsy procedures
- Anesthesia Considerations: If local anesthesia only is planned: no fasting required; If sedation or general anesthesia is planned: NPO (nothing by mouth) 6-8 hours prior to procedure
- Medications: Discontinue anticoagulants (warfarin, apixaban, rivaroxaban) 3-5 days prior or per cardiologist instructions; hold NSAIDs and aspirin 5-7 days prior; hold clopidogrel 5 days prior if possible; continue other routine medications with sips of water if sedation planned
- Pre-Biopsy Laboratory Work: CBC, coagulation studies (PT/INR, PTT, bleeding time), and blood type/cross if major surgery anticipated post-biopsy
- Patient Preparation Instructions: Wear loose, comfortable clothing allowing shoulder access; avoid heavy lifting/strenuous activity 48 hours post-procedure; arrange transportation if sedation planned; bring insurance cards and photo ID
- Imaging Preparation: Bring recent imaging studies (ultrasound, CT, MRI); review with interventional radiologist or surgeon to determine biopsy approach prior to procedure
- Post-Procedure Instructions: Keep biopsy site clean and dry; apply ice for 24 hours as needed; take pain medication as prescribed; wear sling if recommended; report signs of infection, excessive bleeding, or neurovascular changes; return for results discussion in 3-7 business days

How our test process works!